Cartesian Therapeutics
Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.
A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus in tiny trial Results expected Dec 2026 (estimated)
- Could a One-Time cell therapy ease myasthenia gravis? new trial launches Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase 2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…
Phase 1/2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC